AU6786681A

AU6786681A - Red cell storage solution

Info

Publication number: AU6786681A
Application number: AU67866/81A
Authority: AU
Inventors: Gerald A. Grode; Jeffrey E. Miripol
Original assignee: Baxter Travenol Laboratories Inc
Current assignee: Baxter International Inc
Priority date: 1980-02-05
Filing date: 1980-12-29
Publication date: 1981-08-31
Anticipated expiration: 2000-12-29
Also published as: AU540168B2

Description

RED CELL STOPPAGE SOLUTION BACKGROUND OF THE INVENTION

Collected blood may be conventionally centrifuged to remove the plasma and the buffy coat layer, leaving be¬ hind the "packed red cells", as the mass of red cells is 5 substantially separated from the plasma. This is desirable for several reasons, first to collect the plasma for separ¬ ate therapeutic use, but also because it is desirable to administer concentrated red cells during major surgery, to provide the patient with a maximum amount of red cells with

■_jo a minimum of added fluids , to avoid overburdening the patient's vascular system with excess fluids.

Accordingly, it is deemed desirable in many forms of medical practice and blood banking to store the packed red cells separately, apart from a substantial portion of

15 the plasma, for later administration to a patient during major surgery or the like, while the collected plasma finds a separate medical use, for example, administration to another patient or processing into various medical components such as antihemophilic factor and plasma protein fraction.

20. In the long term storage of blood, it has been pre¬ viously reported that a unit of packed red cells may be ad¬ mixed with about 100 ml. of blood plasma, which is far less than normal blood, or, preferably, the packed cells can be reconstituted with about 100 ml. of a solution known as SAG,

25 comprising salt (sodium chloride), adenine, and glucose.

The ^'term "unit" of blood or packed red cells as used herein is as commonly used in blood banking circles , comprising the amount of red cells in a standard single collection of blood (typically, 225 ml. of packed cells, but, of course, sub ect

30 to variation according to the individual donor) . See, for example, the article by Lovric et al. , Medical Journal of Australia, 1977, 2: 183-186.

The packed cells which are reconstituted with SAG solution have been shown to be storable for 35 days with im-

35 proved viability of the red cells, when compared with packed red cells stored in a similar amount of plasma. It has also been suggested to use mannitol, whic is a type of sugar, as a reagent to improve the viability stored blood cells. However, surprisingly, it has been found in accordance with this invention that despite the fact that SAG solution contains abundant sugar already, th addition of mannitol provides a significant improvement in the viability of packed red cells stored in contact there¬ with. Accordingly, longer storage times appear to be poss ble for packed red cells with better viability than has be previously available.

- ^θMP DESCRIFTION OF THE INVENTION

In accordance with this invention, an aqueous red cell storage solution is provided, particularly for admix¬ ture with highly concentrated or packed red cells , for im- proving the viability of the cells upon storage. The solu¬ tion contains, per 100 ml., essentially from 5 to 50 mg. of adenine; from 1000 to 3500 mg. of a sugar such as glucose or fructose; from 400 to 1200 mg. of sodium chloride; and from 250 to 2000 mg. of mannitol. Preferably, per 100 ml. of solution, from 20 to

30 mg. of adenine, from 1500 to 2500 mg. of glucose or fruc¬ tose, from 500 to 1000 mg. of sodium chloride, and from 500 to 1500 mg. of mannitol are present. Particularly, from 700 to 800 mg. of mannitol may be present per 100 ml. of solution, for example, 750 mg..

A specifically preferred solution in accordance with this invention may contain, per 100 ml., about 27 mg. of adenine, 2000 mg. of glucose, 900 mg. of sodium chloride and 750 mg. of mannitol, these solutes being carefully dis- solved in distilled water and then sterilized and sealed in conventional manner.

For example, a conventional triple or quadruple pack blood bag of conventional design for receiving one unit of blood, comprising a donor bag and two or three satellite transfer bags or packs may be utilized, with typically about 60 to 200, and preferably 80 to 150 ml., of the above speci¬ fically described solution being placed in one of the trans¬ fer bags. Preferably, an extra interior seal, openable from the exterior, is provided to the connecting tube between the solution-containing transfer bag and the donor bag adjacent the transfer bag, for example, the CELL-PROOF® closure of the Fenwal Division of Baxter Travenol Laboratories , or the closure of U.S. Patent No. 4,181,140.

A unit of blood may be accordingly collected in conventional manner into the donor bag. The three or four bag system may be conventionally centrifuged, and the plas¬ ma and buffy coat layer can be expressed into an empty trans- fer bag by appropriate manipulation of the clamping and in ternal sealing system provided by the bag system. The red cell storage solution in the first transfer pack may then expressed into the donor bag, and the donor bag may then b sealed and separated from the remaining bags for long term storage.

Following this, the plasma-containing transfer b may be centrifuged to separate platelets, with the platele poor plasma then being expressed from the plasma-containin transfer bag into the transfer pack which formerly contain red cell storage solution in the case of a triple bag. Th transfer packs may be then separated for separate storage and therapeutic administration or other use as desired. T fourth bag of a multiple bag unit may be provided to recei the leucocytes, for example.

Long-term storage of packed red cells at 4° C. under conventional storage conditions for 35 days and more is possible, with the red cells exhibiting improved viabil in accordance with this invention. Preferably, the donor bag contains a usual amoun of CPD preservative. Also, the solution of this invention may contain other ingredients as desired, for example, guanosine, or phosphate, calcium, magnesium or potassium i etc.. The following example is offered for illustrativ purposes only, and is not intended to limit the invention this application, which is as defined in the claims below.

Example. A triple bag system of the conventiona design of the Fenwal BLOOD-PACK® system, containg a donor bag with CPD preservative of the usual type, and two trans fer bags were utilized in this experiment, but also con¬ taining an added inner seal at the first transfer bag, ope able from the exterior, in the tube leading between the do bag and the transfer bag. Where indicated, the first tran fer bag contained 100 ml. of the cell diluent solution des cribed below. In each experiment a unit of blood was collected in the donor bag, centrifuged, and the plasma was expressed from the donor bag to the second transfer bag. Then, the 100 ml. of solution in the first transfer bag was expressed into the donor pack, which was then sealed, sepa- rated from the bag system, and stored for 35 days at 4°C. in conventional manner.

Referring to experiments (a) through (e) as des¬ cribed below, in experiment (a), the 100 ml. of solution in the first transfer bag was simply saline solution containing 900 mg. of sodium chloride per 100 ml..

In experiment (b) , no diluent solution at all was used, with the packed cells being stored in their undiluted configuratio .

In experiment (c) , the packed cells were diluted with 100 ml. of plasma, which was simply reexpressed back to the cells from the second transfer bag containing the plasma.

In experiment (d) below, the 100 ml. of solution placed in the transfer pack contained 1000 mg. of glucose,* approximately 17 mg. of adenine, and about 800 mg. of sodium chloride. No mannitol was present.

In experiment (e) below, the 100 ml. of solution in the first transfer pack was an embodiment of the solution of this invention, containing 27 mg. of adenine; 2000 mg. of glucose; approximately 500 mg. of sodium chloride; and 750 mg. of mannitol.

After processing of the blood in accordance with the technique described above, each of the donor bags of the five experiments (a) through (e) were stored at 4°C. for 35 days.

At the conclusion of the 35 days, the plasma hemo¬ globin was measured in terms of mg. per 100 ml. , and the red cell ATP was measured and expressed in Table I below as micromoles per gram of red cell hemoglobin. TABLE I

PLASMA

TREATMENT CONDITIONS HEMOGLOBIN ATP (Micromo1es/g. PRIOR TO STORAGE (tag./lOO ml.) Red Cell Hemoglobin)

(a) packed cells with saline solution more than 1000 about 1.5

(b) packed cells only more than 1000 about 2.5

(c) packed cells plus 100 ml. plasma 200 about 1.75

(d) saline, adenine, glucose solution without mannitol 500 about 4

(e) the solution of this invention con¬ taining mannitol 180 about 5

Accordingly, it can be seen that in accordance with this invention, substantially decreased plasma hemo¬ globin levels, and significantly increased ATP levels, are achieved on 35 day storage of packed cells, when compared with prior art techniques.

Claims

THAT WHICH IS CLAIMED IS:

1. An aqueous cell storage solution which contains per 100 ml. of solution essentially from 5 to 50 mg. of adenine; from 1000 to 3500 mg. of a sugar selected from the group consisting of glucose and fructose; from 400 to 1200 g of sodium chloride; and from 250 to 2000 mg. of mannitol.

2. The solution of Claim 1 which contains, per 100 ml. of solution, from 20 to 30 mg. of adenine.

3. The solution of Claim 1 which contains, per 100 ml. of solution, from 1500 to 2500 milligrams of said sugar.

4. The solution of Claim 3 in which said sugar is glucose.

5. The solution of Claim 1 which contains, per 100 ml. of solution, from 500 to 1000 mg. of sodium chloride.

6. The solution of Claim 1 which contains, per 100 ml. of solution, from 500 to 1500 mg. of mannitol.

7. The solution of Claim 6 which contains, per 100 ml. of solution, from 700 to 800 mg. of mannitol.

8. An aqueous red cell storage solution which contains, per 100 ml. of solution, essentially from 20 to 3 mg. of adenine; from 1500 to 2500 mg. of a sugar selected from the group consisting of glucose and fructose; from 500 to 1000 mg. of sodium chloride; and from 250 to 2000 mg. of mannito1.

9. The solution of Claim 8 in which said sugar i glucose.

10. The solution of Claim 9 in which from 700 to 800 mg. of mannitol are present per 100 ml. of solution.

11. A unit of red blood cells, intermixed with from 60 to 200 ml. of an aqueous red cell storage solution which contains, per 100 ml. of said storage solution, essen tially from 5 to 50 mg. of adenine; from 1000 to 3500 mg. of a sugar selected from the group consisting of glucose and fructose; from 400 to 1200 mg. of sodium chloride; and from 250 to 2000 mg. of mannitol.

12. The unit of packed blood cells and mixed solution of Claim 11 in which CPD preservative is present

13. A unit of packed red blood cells, mixed with from 80 to 150 ml. of an aqueous red cell storage solution which contains, per 100 ml. of solution, essentially from -20 to 30 mg. of adenine; from 1500 to 2500 mg. of a sugar selected from the group consisting of glucose and fructose; from 500 to 1000 mg. of sodium chloride; and from 500 to 1500.mg. of mannitol.

14. The unit of packed blood cells and mixed solution of Claim 13 in which said sugar is glucose.

15. The unit of packed blood cells and mixed solution of Claim 14 in which from 700 to 800 mg. of manni- 5 tol is present per 100 ml. of said solution.

16. The unit of packed blood cells and mixed solution of Claim 13 in which CPD blood preservative is present.

k